Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, …

EODHD | 08 May 2025

Kimbell Royalty Partners Announces Record First Quarter 2025 Results

Record Oil, Natural Gas and NGL Revenues, Net Income of $25.9 million, Record Consolidated Adjusted EBITDA and Record Cash Available for Distribution Q1 2025 Run-Rate Daily Production of 25,841 Boe/d (6:1) Including a Full-Quarter of Acquired Production; Exceeds Mid-Point of Guidance Redeemed 50% of …

EODHD | 08 May 2025

Ligand Reports First Quarter 2025 Financial Results

Ligand Pharmaceuticals First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share …

EODHD | 08 May 2025

LENSAR Reports First Quarter 2025 Results and Provides Business Update

14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months …

EODHD | 08 May 2025

Nexstar Media Group Reports First Quarter Net Revenue of $1.23 Billion

Q1 Net Revenue Drives Net Income of $97 Million, Adjusted EBITDA of $381 Million, Net Cash Provided by Operating Activities of $337 Million and Adjusted Free Cash Flow of $348 Million Record First Quarter Distribution Revenue Quarterly Return of Capital to Shareholders of $132 …

EODHD | 08 May 2025

ProQR Announces First Quarter 2025 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and …

EODHD | 08 May 2025

Papa Johns Announces First Quarter 2025 Financial Results

LOUISVILLE, Ky., May 08, 2025--(BUSINESS WIRE)--Papa John’s International, Inc. (Nasdaq: PZZA) ("Papa Johns®") (the "Company") today announced financial results for the first quarter ended March 30, 2025. Highlights North America comparable sales were down 3% from a year ago as Domestic Company-owned restaurants were …

EODHD | 08 May 2025

D-Wave Reports First Quarter 2025 Results

Record Quarterly Revenue of $15 Million - Up Over 500% Year over Year Record Quarterly GAAP Gross Profit of $13.9 Million Record Quarter End Cash Position of $304.3 Million PALO ALTO, Calif., May 08, 2025--(BUSINESS WIRE)--D-Wave Quantum Inc., (NYSE: QBTS) ("D-Wave" or the "Company") …

EODHD | 08 May 2025

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus …

EODHD | 08 May 2025

SharkNinja Reports First Quarter 2025 Results

Raises Fiscal Year 2025 Outlook on Key Metrics NEEDHAM, Mass., May 08, 2025--(BUSINESS WIRE)--SharkNinja, Inc. ("SharkNinja" or the "Company") (NYSE: SN), a global product design and technology company, today announced its financial results for the first quarter ended March 31, 2025. Highlights for the …

EODHD | 08 May 2025
Support

Hi! How can we help you today?

Loading…